FDA approves Yuflyma as Adalimumab’s ninth biosimilar
The US Food and Drug Administration (FDA) has approved the biosimilar adalimumab-aaty (Yuflyma) in a highly concentrated citrate-free formulation, the manufacturer, Celltrion USA, announced today. It is the ninth biosimilar of adalimumab (Humira) to be approved in the United States. Yuflyma is approved for the treatment of adult patients with rheumatoid arthritis, psoriatic arthritis, ankylosing … Read more